THE European Medicines Agency
has released a revised guideline for
public consultation, describing how
pharmaceutical companies should
address the quality aspects of
biosimilar medicines.
The previous guidance was
developed in 2006, explaining the
requirements for the manufacture
and comparability testing for
biological medicines claiming to be
similar to another medicine already
on the market.
The document can be viewed at
http://bit.ly/EMAbiosimilarguide.
The above snippet is the first part of an article sent to subscribers in Pharmacy Daily's issue from 07 Jun 12
Established in 2007, Pharmacy Daily is Australia's leading pharmacy industry publication, and is sent as a free subscription to people across the industry as a PDF newsletter every weekday.
To sign up for a free subscription, click on the button at right.
